96
Participants
Start Date
July 12, 2011
Primary Completion Date
June 30, 2015
Study Completion Date
January 31, 2017
vorinostat
Vorinostat 400mg/day will be administered on day 1 to 7 and day 15 to 21 orally on a 28 day cycle in the arm with combination of vorinostat and bevacizumab. Vorinostat will be administered orally. Vorinostat capsules should not be opened or crushed and must be administered whole.
bevacizumab
Bevacizumab 10mg/kg will be administered on day 1 and 15 intravenously on a 28 day cycle in both arms.
Baylor University Medical Center, Dallas
Collaborators (2)
M.D. Anderson Cancer Center
OTHER
Genentech, Inc.
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Brain Tumor Trials Collaborative
OTHER
Ohio State University
OTHER
Northwestern University Feinberg School of Medicine
OTHER
UF Health Cancer Center at Orlando Health
UNKNOWN
Baylor Health Care System
OTHER
MUSC Hollings Cancer Center
UNKNOWN
University of Utah Health System
UNKNOWN
University of Washington
OTHER
Henry Ford Health System
OTHER
Columbia University
OTHER
Rush University Medical Center
OTHER
Endeavor Health
OTHER
The Cleveland Clinic
OTHER
University of North Carolina, Chapel Hill
OTHER
Washington University School of Medicine
OTHER
Texas Oncology-Austin
UNKNOWN
National Cancer Institute (NCI)
NIH